ClinicalTrials.gg
TerminatedNCT03866798Updated Sep 24, 2024Results posted

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

A Phase 4 interventional study of Panzyga in Chronic Immune Thrombocytopenia, sponsored by Octapharma. Terminated at 8 sites in United States. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Octapharma · Phase 4, Interventional, and Treatment

Why this study was terminated
FDA released Octapharma from the pediatric post marketing requirement.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States — 18 open to participants now, 22 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United States.

Enrollment
87th of 94
6 · median 42
Started
2020
with 7 others
Phase 4
2 of 110
none open now
Registered
64th of 110
by date

Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, this one is the 87th largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2020, is one of 2 in phase 4, and was the 64th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

18 of the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.

03

Conditions studied

  • Chronic Immune Thrombocytopenia
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females and males aged from ≥1 year to \<18 years old
  2. Confirmed diagnosis of Chronic Immune Thrombocytopenia (ITP) according to American Society of Hematology (ASH) 2019 guidelines
  3. count \<30x10\^9/L at the Baseline Visit
  4. Voluntarily given written (provided by patient's parent or legal guardian) and assent (provided by patient [if age-appropriate per IRB (Institutional Review Board) requirements])
  5. Sexually active females who have been using at least 1 acceptable form of for a minimum of 30 days (or a minimum of 3 months for hormonal contraceptives) prior to the Screening visit and must agree to use at least 1 acceptable method of contraception throughout the study and for 30 days after the last dose of PANZYGA. Acceptable methods of birth control for this study include: intrauterine device (IUD), hormonal contraception, male or female condom, spermicide gel, diaphragm, sponge, or cervical cap. For non-sexually active females who have begun menstruating, abstinence is considered an acceptable method of birth control.
  6. Parent or legal guardian must agree and be willing to assist the participant attend study visits, and to follow all protocol requirements and instructions of the study doctor

Exclusion criteria

Exclusion Criteria:

  1. Thrombocytopenia secondary to other diseases (such as Acquired Immunodeficiency Syndrome [AIDS] or systemic lupus erythematosus [SLE]), drug-related thrombocytopenia, or congenital thrombocytopenia
  2. Administration of intravenous immunoglobulin (IGIV) or anti-D immunoglobulin within 3 weeks (+/- 3 days) before enrollment
  3. Administration of thrombopoietin receptor agonists when the dose has NOT been stable within 3 weeks before enrollment and a dosage change is planned before Day 32
  4. Administration of oral when the dose has NOT been stable during the preceding 2 months (2 weeks for long-term therapy) and a dosage change is planned before Day 32 (Note: topical agents and inhaled corticosteroid therapy use is permitted)
  5. Administration of long-term anti-prolific agents or attenuated androgen therapy when the dose has NOT been stable during the preceding 2 months and a dosage change is planned before Day 32
  6. Nonresponsive to previous treatment with IGIV or anti-D immunoglobulin
  7. Evidence of an active major bleeding episode at Screening
  8. Splenectomy in the previous 3 months or planned splenectomy throughout the study period
  9. Evans syndrome (experiencing active disease with 2 out of 3 of the following: thrombocytopenia, autoimmune hemolytic anemia, and/or autoimmune neutropenia)
  10. Known or suspected (HIV), virus (HBV), and/or virus (HCV) infections
  11. Emergency surgery in the previous 4 weeks
  12. Severe liver and/or kidney disease ( [ALT] >3x (ULN), aspartate aminotransferase [AST] >3x upper limit of normal (ULN), and/or creatinine >120 µmol/L)
  13. History of severe to blood or plasma derived products, or any component of the PANZYGA
  14. Known immunoglobulin A (IgA) deficiency and antibodies against IgA
  15. History of, or suspected alcohol or drug abuse in the previous year
  16. Females who are pregnant or nursing
  17. Unable or unwilling to comply with the study protocol
  18. Receipt of any other medicinal product within 3 months before study entry
  19. Risk factors* for thromboembolic events in whom the risks outweigh the potential benefit of PANZYGA treatment.
  20. Any other condition(s), that in the Investigator's opinion, make it undesirable for the patient to participate in the study or may interfere with protocol compliance.

    • Risk factors include, but are not limited to: obesity, advanced age, hypertension, diabetes, a history of atherosclerosis/vascular disease or thrombotic events, hyperlipidemia, multiple cardiovascular risk factors, acquired or inherited thrombophilic disorders, prolonged periods of immobilization, severe hypovolemia, central venous catheterization, active and/or known or suspected hyperviscosity.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Panzyga

    Panzyga

    Biological: Panzyga

Interventions

  • BiologicalPanzyga

    Immune Globulin, intravenous, human-ifas

06

What researchers measure

Primary outcomes

  1. Platelet Count Increase

    Number of subjects with an increase in platelet count at least once to ≥50 × 10\^9/L within 7 days after the first infusion, i.e., by Day 8 (increase must have occurred at least once on any day up to and including Day 8).

    Time frame: 8 Days

Secondary outcomes

  1. Days to Reach Platelet Count of at Least 50x10^9/L

    Number of days for subjects to reach Platelet Count of at least 50x10\^9/L after infusion

    Time frame: Through study completion, up to 37 days

  2. Duration of Platelet Response

    Number of days the platelet count remains above at least 50x10\^9/L

    Time frame: Through study completion, up to 37 days

  3. Maximum Platelet Count

    Maximum platelet count (10\^9/L) for each subjects

    Time frame: Through study completion, up to 37 days

07

Results

Posted Aug 7, 2024

Participant flow

Six subjects aged ≥1 year to \<18 years were recruited between 21-Jan-2020 and 19-Sep-2023. The subjects were enrolled at five research sites across the United States, with a total of eight research sites activated in the study.

Participant flow — Overall Study
MilestonePanzyga
Started6
Completed6
Not completed0

Outcome measures

PrimaryPlatelet Count Increase

Number of subjects with an increase in platelet count at least once to ≥50 × 10\^9/L within 7 days after the first infusion, i.e., by Day 8 (increase must have occurred at least once on any day up to and including Day 8).

Time frame:
8 Days
Reported as:
Count of participants · Participants
Platelet Count Increase
ParticipantsPanzyga
Platelet Count Increase4
SecondaryDays to Reach Platelet Count of at Least 50x10^9/L

Number of days for subjects to reach Platelet Count of at least 50x10\^9/L after infusion

Time frame:
Through study completion, up to 37 days
Reported as:
Count of participants · Participants
Days to Reach Platelet Count of at Least 50x10^9/L
ParticipantsPanzyga
2 days3
3 days1
Did not reach Platelet Count of at least 50x10^9/L2
SecondaryDuration of Platelet Response

Number of days the platelet count remains above at least 50x10\^9/L

Time frame:
Through study completion, up to 37 days
Reported as:
Count of participants · Participants
Duration of Platelet Response
ParticipantsPanzyga
6 days1
7 days1
33 days1
34 days1
Did not reach Platelet Count of at least 50x10^9/L2
SecondaryMaximum Platelet Count

Maximum platelet count (10\^9/L) for each subjects

Time frame:
Through study completion, up to 37 days
Reported as:
Count of participants · Participants
Maximum Platelet Count
ParticipantsPanzyga
99 (10^9/L)1
11 (10^9/L)1
516 (10^9/L)1
386 (10^9/L)1
204 (10^9/L)1
30 (10^9/L)1

Adverse events

Collected over 3 years, 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panzyga0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent other events
Most frequent other events
EventPanzyga
HeadacheNervous system disorders2/6
NauseaGastrointestinal disorders2/6
VomitingGastrointestinal disorders2/6
MyalgiaMusculoskeletal and connective tissue disorders1/6
NeutropeniaBlood and lymphatic system disorders1/6
EpistaxisRespiratory, thoracic and mediastinal disorders1/6
Mouth haemorrhadeGastrointestinal disorders1/6
Dental CariesGastrointestinal disorders1/6
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders1/6
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Panzyga
<=18 years6
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Panzyga
Female2
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panzyga
Hispanic or Latino3
Not Hispanic or Latino3
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Panzyga
United States6
08

Study locations

8 sites
  • Octapharma Research Site
    Sacramento, California 95817, United States
  • Octapharma Research Site
    Minneapolis, Minnesota 55404, United States
  • Octapharma Research Site
    Rochester, Minnesota 55905, United States
  • Octapharma Research Site
    Columbus, Ohio 43205, United States
  • Octapharma Research Site
    Toledo, Ohio 43606, United States
  • Octapharma Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Octapharma Research Site
    Providence, Rhode Island 02903, United States
  • Octapharma Research Site
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Sep 2023, 43 months.

Results were first posted in Aug 2024, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Mar 7, 2019
StartActual
Jan 21, 2020
Primary completionActual
Sep 19, 2023
CompletionActual
May 17, 2024
Results first posted
Aug 7, 2024
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03866798
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Mar 7, 2019
Start date
Jan 21, 2020
Primary completion
Sep 19, 2023
Completion
May 17, 2024
Results posted
Aug 7, 2024
Last update
Sep 24, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panzyga

Start the discussion